Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China
- PMID: 40809228
- PMCID: PMC12340267
- DOI: 10.21037/jtd-24-1703
Epidemiological features and risk factors of SARS-CoV-2 reinfection: a retrospective cohort analysis in Xiamen, China
Abstract
Background: Recently, surges in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections in China have raised public concern. We investigated the epidemiological features and risk factors for SARS-CoV-2 reinfection in China.
Methods: A retrospective cohort study was conducted in Xiamen, China (2021-2023) with two subcohorts: Delta-Omicron (cohort 1) and Omicron-Omicron (cohort 2). Descriptive analysis and ensemble modeling were employed to evaluate reinfections.
Results: A total of 327 cases without fatalities were included. Reinfections accounted for 14.68% of cases, with 22.51% in cohort 1 and 3.68% in cohort 2. Compared with primary infections (PIs) (99.69% symptomatic, 56.54% hospitalized), reinfections were less severe, with fewer symptomatic instances (47.92%) and hospitalizations (4.65%). The majority of reinfections (83.33%) occurred following the relaxation of strict public health and social measures. The median time interval between PI and reinfection was longer for cohort 1 (462 days) than for cohort 2 (280 days). Reinfection risks were noted among lesser developed regions, those without persistent PI, those with primary Delta variant infection, government and hospital workers, and unvaccinated individuals.
Conclusions: SARS-CoV-2 reinfections are generally less severe and are influenced by the relaxation of control measures, viral evolution, and changing patterns of population immunity and contact; this underscores the need for ongoing surveillance and targeted public health strategies to manage future infection waves.
Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); coronavirus disease 2019 (COVID-19); primary infection (PI); reinfection.
Copyright © 2025 AME Publishing Company. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1703/coif). The authors have no conflicts of interest to declare.
Figures



Similar articles
-
Dynamic monitoring of antibody titers in people living with HIV during Omicron epidemic: comparison between unvaccinated and vaccinated individuals.BMC Infect Dis. 2025 Jul 30;25(1):962. doi: 10.1186/s12879-025-11387-3. BMC Infect Dis. 2025. PMID: 40739195 Free PMC article.
-
Reinfection with SARS-CoV-2 in the Omicron Era is Associated with Increased Risk of Post-Acute Sequelae of SARS-CoV-2 Infection: A RECOVER-EHR Cohort Study.medRxiv [Preprint]. 2025 Mar 30:2025.03.28.25324858. doi: 10.1101/2025.03.28.25324858. medRxiv. 2025. PMID: 40196285 Free PMC article. Preprint.
-
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3. Cochrane Database Syst Rev. 2023. PMID: 38032024 Free PMC article.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article.
-
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun. PLoS Med. 2023. PMID: 37285378 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous